BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29279867)

  • 1. In vivo genome editing improves motor function and extends survival in a mouse model of ALS.
    Gaj T; Ojala DS; Ekman FK; Byrne LC; Limsirichai P; Schaffer DV
    Sci Adv; 2017 Dec; 3(12):eaar3952. PubMed ID: 29279867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model.
    Duan W; Guo M; Yi L; Liu Y; Li Z; Ma Y; Zhang G; Liu Y; Bu H; Song X; Li C
    Gene Ther; 2020 Apr; 27(3-4):157-169. PubMed ID: 31819203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of a Mouse Model of ALS by In Vivo Base Editing.
    Lim CKW; Gapinske M; Brooks AK; Woods WS; Powell JE; Zeballos C MA; Winter J; Perez-Pinera P; Gaj T
    Mol Ther; 2020 Apr; 28(4):1177-1189. PubMed ID: 31991108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model.
    Chen YA; Kankel MW; Hana S; Lau SK; Zavodszky MI; McKissick O; Mastrangelo N; Dion J; Wang B; Ferretti D; Koske D; Lehman S; Koszka K; McLaughlin H; Liu M; Marshall E; Fabian AJ; Cullen P; Marsh G; Hamann S; Craft M; Sebalusky J; Arnold HM; Driscoll R; Sheehy A; Luo Y; Manca S; Carlile T; Sun C; Sigrist K; McCampbell A; Henderson CE; Lo SC
    Gene Ther; 2023 May; 30(5):443-454. PubMed ID: 36450833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-Mediated Gene Correction to Understand ALS.
    Yun Y; Ha Y
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.
    Leyton-Jaimes MF; Kahn J; Israelson A
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14755-14760. PubMed ID: 31262807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model.
    Stoica L; Todeasa SH; Cabrera GT; Salameh JS; ElMallah MK; Mueller C; Brown RH; Sena-Esteves M
    Ann Neurol; 2016 Apr; 79(4):687-700. PubMed ID: 26891182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
    Abati E; Bresolin N; Comi G; Corti S
    Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1
    Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T
    Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs.
    Wang L; Yi F; Fu L; Yang J; Wang S; Wang Z; Suzuki K; Sun L; Xu X; Yu Y; Qiao J; Belmonte JCI; Yang Z; Yuan Y; Qu J; Liu GH
    Protein Cell; 2017 May; 8(5):365-378. PubMed ID: 28401346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient.
    Coatti GC; Frangini M; Valadares MC; Gomes JP; Lima NO; Cavaçana N; Assoni AF; Pelatti MV; Birbrair A; de Lima ACP; Singer JM; Rocha FMM; Da Silva GL; Mantovani MS; Macedo-Souza LI; Ferrari MFR; Zatz M
    Stem Cell Rev Rep; 2017 Oct; 13(5):686-698. PubMed ID: 28710685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single copy/knock-in models of ALS SOD1 in C. elegans suggest loss and gain of function have different contributions to cholinergic and glutamatergic neurodegeneration.
    Baskoylu SN; Yersak J; O'Hern P; Grosser S; Simon J; Kim S; Schuch K; Dimitriadi M; Yanagi KS; Lins J; Hart AC
    PLoS Genet; 2018 Oct; 14(10):e1007682. PubMed ID: 30296255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of survival motor neuron improves neuromuscular function and motor neuron survival in mutant SOD1 mice.
    Turner BJ; Alfazema N; Sheean RK; Sleigh JN; Davies KE; Horne MK; Talbot K
    Neurobiol Aging; 2014 Apr; 35(4):906-15. PubMed ID: 24210254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
    Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
    J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
    Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS.
    Deng HX; Zhai H; Shi Y; Liu G; Lowry J; Liu B; Ryan ÉB; Yan J; Yang Y; Zhang N; Yang Z; Liu E; Ma YC; Siddique T
    Commun Biol; 2021 Mar; 4(1):396. PubMed ID: 33767386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.